Jpmorgan Chase & CO Spectrum Pharmaceuticals Inc Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.32 - $0.52 $2,502 - $4,066	-7,821 Reduced 66.59%	3,924 $1,000
Q3 2022 Nov 14, 2022	SELL	$0.43 - $1.56 $13,816 - $50,124	-32,131 Reduced 73.23%	11,745 $5,000
Q2 2022 Aug 11, 2022	SELL	$0.7 - $1.4 $278,415 - $556,830	-397,736 Reduced 90.06%	43,876 $34,000
Q1 2022 May 11, 2022	SELL	$0.63 - $1.59 $31,527 - $79,569	-50,044 Reduced 10.18%	441,612 $571,000
Q4 2021 Feb 10, 2022	SELL	$1.27 - $2.42 $37,287 - $71,051	-29,360 Reduced 5.64%	491,656 $624,000
Q3 2021 Nov 12, 2021	BUY	$2.15 - $3.82 $1.12 Million - $1.99 Million	521,016 New	521,016 $1.14 Million

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.